☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
LEXEO
Lexeo Reports Initial Expression and Biomarker Data of LX1001 in P-I/II Clinical Trial for the Treatment of Alzheimer’s Disease
March 3, 2022
LEXEO Receives the US FDA’s IND Clearance of LX2006 for the Treatment of Friedreich’s Ataxia Cardiomyopathy
February 17, 2022
Load more...
Back to Home
Modal title
×
Modal body text goes here.